Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 606
- Registration Number
- NCT04762459
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center, Shenzhen, China
A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Taizhou HoudeAoke Biomedical Co., Ltd.
- Target Recruit Count
- 94
- Registration Number
- NCT04755543
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Henan Cancer Hospital & Insititute, Zhengzhou, Henan, China
🇨🇳Liaoning Cancer Hospital & Insititute, Shenyang, Liaoning, China
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2024-08-23
- Target Recruit Count
- 38
- Registration Number
- NCT04753879
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 13
- Registration Number
- NCT04747470
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸NEXT oncology, San Antonio, Texas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Study of AZD2811 + Durvalumab in ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT04745689
- Locations
- 🇪🇸
Research Site, Valencia, Spain
A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Akeso
- Target Recruit Count
- 28
- Registration Number
- NCT04736810
- Locations
- 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
A Phase 1/2 Study of SC-43 in Combination With Cisplatin
- Conditions
- Interventions
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- RaND Biosciences
- Target Recruit Count
- 100
- Registration Number
- NCT04733521
Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Third Military Medical University
- Target Recruit Count
- 80
- Registration Number
- NCT04731909
- Locations
- 🇨🇳
Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04722523
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 201
- Registration Number
- NCT04716933
- Locations
- 🇨🇳
Fujian Provincial Cancer Hospital ( Site 0102), Fuzhou, Fujian, China
🇨🇳Cancer Hospital Affiliated to Xinjiang Medical University ( Site 0110), Urumuqi, Xinjiang, China
🇨🇳The First Affiliated Hospital of Wenzhou Medical University ( Site 0124), Wen Zhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.